Products
The currently held novel IP includes e.g.
- Diagnostic markers and therapeutic targets of alcohol addiction, atherosclerosis, coronary heart disease, hypertension, obesity and type 2 diabetes
- Biochemical markers of energy efficiency, a key component of obesity,
- Nutrigenetic markers of obesity and type 2 diabetes,
- Personalized health test of usefulness of vitamin E and
- Pharmaceutical composition with enhanced health effects of vitamin D
The company carries out validation of diagnostic (Dx) markers and therapeutic (Rx) targets: the company tests genetic and biomarker discoveries for replication in samples and data accessed by MAS. The company has large biobanks of clinical data and blood, DNA, RNA, serum, plasma and urine samples and comprehensive clinical data for over 10,000 subjects, covering all common diseases. MAS also carries out clinical trials with obesity, dyslipoproteinemia, hypertension and T2D medicines.
